MVP expression is related to IGF1-R in cervical carcinoma patients treated by radiochemotherapy.
OBJECTIVE
To assess the expression of MVP in cervix carcinoma patients treated by radiochemotherapy, its relation to clinical and pathologic prognostic factors and its role in predicting clinical outcome. In addition the relation to IGF-1R expression in this cohort of patients will be explored.


METHODS
Sixty consecutive patients suffering from localized cervix carcinoma were prospectively included in this study from July 1999 to December 2003. Follow-up was closed in November 2007. Patients were staged following the TNM classification. All patients received pelvic radiation (45-64.80 Gy in 1.8-2 Gy fractions) followed brachytherapy and concomitant cisplatin at 40 mg/m(2)/week doses. MVP expression was studied by immunohistochemistry in paraffin-embedded tumour tissue.


RESULTS
MVP was expressed in 58 patients (96.7%) and no relation was found with clinicopathological variables. High MVP expression was related to high IGF1-R expression (p=0.023). Complete response after treatment was observed in 50 patients (83.3%). Clinical stage of the disease and clinical response to radiochemotherapy were the most important prognostic factors related to survival. High MVP and IGF-1R tumour expression was strongly related to poor local and regional disease-free survival (p=0.006), distant disease-free survival (p=0.050), disease-free survival (p=0.006), and cause-specific survival (p=0.007) in patients achieving a complete response.


CONCLUSIONS
MVP and IGF-1R expression were related in clinical cervical tumours and confer reduced long-term local control in patients who achieved clinical complete response to radiochemotherapy.
Lloret
Marta
M
Radiation Oncology, Dr Negrin University Hospital, Las Palmas de Gran Canaria, Spain. mllosae@hotmail.com
Lara
Pedro Carlos
PC
Bordón
Elisa
E
Rey
Agustin
A
Falcón
Orlando
O
Apolinario
Rosa Maria
RM
Clavo
Bernardino
B
Ruiz
Ana
A
D015331:Cohort Studies; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D011446:Prospective Studies; D017526:Receptor, IGF Type 1 / Q000096:biosynthesis*; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000532:radiotherapy / Q000628:therapy*; D020394:Vault Ribonucleoprotein Particles / Q000096:biosynthesis*; D000099187:Major Vault Protein
D017526:Receptor, IGF Type 1; D020394:Vault Ribonucleoprotein Particles; D000099187:Major Vault Protein